Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsCash from RestructuringChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Itron (ITRI) Capital Expenditures: 2009-2025

Historic Capital Expenditures for Itron (ITRI) over the last 17 years, with Sep 2025 value amounting to $4.4 million.

  • Itron's Capital Expenditures fell 33.25% to $4.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.8 million, marking a year-over-year decrease of 15.94%. This contributed to the annual value of $30.6 million for FY2024, which is 13.68% up from last year.
  • According to the latest figures from Q3 2025, Itron's Capital Expenditures is $4.4 million, which was down 26.52% from $6.0 million recorded in Q2 2025.
  • In the past 5 years, Itron's Capital Expenditures ranged from a high of $11.4 million in Q1 2021 and a low of $4.2 million during Q3 2022.
  • Over the past 3 years, Itron's median Capital Expenditures value was $6.6 million (recorded in 2024), while the average stood at $6.6 million.
  • In the last 5 years, Itron's Capital Expenditures plummeted by 52.95% in 2022 and then soared by 76.51% in 2023.
  • Over the past 5 years, Itron's Capital Expenditures (Quarterly) stood at $6.9 million in 2021, then dropped by 29.56% to $4.9 million in 2022, then spiked by 76.51% to $8.6 million in 2023, then rose by 12.87% to $9.7 million in 2024, then slumped by 33.25% to $4.4 million in 2025.
  • Its Capital Expenditures stands at $4.4 million for Q3 2025, versus $6.0 million for Q2 2025 and $4.6 million for Q1 2025.